The results from both preclinical studies in rats and a human clinical trial with BMS-986158 treatment revealed that Nuclear Factor Erythroid 2 (NFE2) and Platelet Factor 4 (PF4, CXCL4) genes are desirable biomarkers for predicting the risk of thrombocytopenia following BET inhibition. This evidence concerns the gene DNER and Thrombocytopenia.